Dr. Yardley on Unmet Need for Patients With HER2+ Breast Cancer

Denise A. Yardley, MD
Published: Tuesday, Aug 02, 2016


Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses unmet treatment needs for patients with HER2-positive breast cancer.

Several developments have been made in the field of HER2-positive breast cancer, particularly with the additions of trastuzumab (Herceptin) and pertuzumab (Perjeta).

However, researchers are trying to expand the number of HER2 agents available for these patients, Yardley explains, which are being explored in ongoing clinical trials. 
SELECTED
LANGUAGE

Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses unmet treatment needs for patients with HER2-positive breast cancer.

Several developments have been made in the field of HER2-positive breast cancer, particularly with the additions of trastuzumab (Herceptin) and pertuzumab (Perjeta).

However, researchers are trying to expand the number of HER2 agents available for these patients, Yardley explains, which are being explored in ongoing clinical trials. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x